Intralipid for repeated implantation failure (RIF): a randomized controlled trial

The role of immunotherapy in in vitro fertilization and recurrent pregnancy loss: a systematic review and meta-analysis

“…The method of randomization was by permuted blocks in three studies (59,60,62), and it was random assigned in seven (56-58, 61, 64, 66, 68). In five studies the method of randomization was not clear (63,65,67,69,70). Allocation concealment was in place in three studies only (56,60,62), and it was not clearly documented in the others.…”

“…In total, 959 women were randomized to treatment with immunotherapies and 896 women were randomized to placebo or no treatment. Four of these studies were published only as conference abstract (58,63,67,70). The characteristics and methodological quality of the included trials are summarized in Supplemental Table 1.…”

“…Six studies included patients undergoing IVF (56-59, 61, 62), and the other nine included women undergoing IVF with previous history of RIF (60,(63)(64)(65)(66)(67)(68)(69)(70). RIF was defined as at least three episodes of implantation failure in three studies (60, 63, 65) and as at least two episodes of implantation failure in two studies (66,67); in the other four studies the number of episodes of previous implantation failure was not clearly described (64,(68)(69)(70).…”

The Effect of Fat Emulsion Intralipid 20% in Reproductive Outcome for Patients With Multiple Implantation Failure

“…Another study showed intralipid suppresses in vivo abnormal NK-cell functional activity and implied that Intralipid can modulate abnormal NK activity in women with reproductive failure (10). In 2016, AbdolmohammadiVahid et al recommended the use of immunosuppressive or immunomodulator agents since the imbalance of the immune system during implantation or pregnancy may lead to implantation failure or miscarriage (13).…”

“…When used in ICSI cycles with patients with RIF, intravenous intralipid 20% infusion improves the clinical pregnancy, the implantation, and the live birth rate (10).…”